secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001140361-25-018277
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025
--------------------------------------------------------------------------------

- Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).
- Only 4.3% of 2 mg/kg group had >10 kPa liver stiffness increase vs 12.5% placebo (p=0.02).
- Safety profile comparable to placebo; no drug-related serious adverse events reported.
- NAVIGATE trial: 355 patients randomized 1:1:1 to belapectin 2/4 mg/kg or placebo every other week for 18 months.
- Data presented as late-breaking oral at EASL 2025 Congress on May 10, 2025 in Amsterdam.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/0001140361-25-018277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/ef20048562_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-018277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer